Innovative patient monitoring solutions

A world without anesthesia and respiratory-related complications

Read more


Presentation of Q4 2022 report

CEO Pia Renaudin presented the fourth quarter 2022 report on February 1, 14:00 CET.

Latest corporate news

Press Releases

Neuromuscular blockade management guidelines

New guidelines recommend Senzime's type of technology

Latest guidelines from both ESAIC European Society of Anaesthesiology and Intensive Care and American Society of Anesthesiologists (ASA) strongly recommend the use of quantitative monitoring neuromuscular blockade.

TetraGraph is a quantitative neuromuscular monitor, based on state-of-the-art EMG technology, enabling you as a clinican to make confident decisions from start to finish of a procedure.

A Swedish medical device company

Senzime develops, manufactures and markets CE- and FDA-cleared patient monitoring systems.

Our vision is a world without anesthesia and respiratory-related complications.

CEO Statement

High growth in the USA driven by new business customers and increased use of disposables

Pia Renaudin, CEO
November 2022

Contact us

Want to know more?

How can Senzime’s innovative patient monitoring solutions help to eliminate in-hospital complications?
Contact us today.